Abstract
Secukinumab shows a highly favourable safety profile, particularly in comparison with standard types of treatment, such as methotrexate use, but also when compared with TNF-alfa blockers. The use of secukinumab is not accompanied by organ toxicity, serious infections, multiple sclerosis, reactivation of latent tuberculosis or hepatitis B, leukaemia/lymphoma, and non-melanoma skin cancers.
The drug has been shown to have therapeutic effect as well as saftey and can be accepted as standard in long-term psoriasis treatment.